Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.


2024-12-22	6.76 -10.95 %
2023-12-31	7.59 44.14 %
2022-12-31	5.27 -78.45 %
2021-12-31	24.43 2.16 %
2020-12-31	23.91 39.94 %
2019-12-31	17.09 -96.09 %
2018-12-31	436.63 Infinity %
2017-12-31	0 0 %

Helius Medical Technologies, Inc.

HSDT | NASDAQ Capital Market

As of 2024-12-22, the Price-to-Sales (P/S) Ratio for Helius Medical Technologies, Inc. was 6.76, reflecting a -10.95% fluctuation.